WuXi PharmaTech (Cayman) Inc., an open-access R&D capability and technology platform company with operations in China and the U.S., has established a representative office in the Tel Aviv area of Israel. 
 
The new office will promote WuXi’s platform of R&D services to local customers, and will also collaborate with Pontifax, a healthcare-dedicated venture capital firm based in Israel, to invest in promising local technologies that can potentially advance WuXi’s capabilities.
 
“We welcome WuXi’s presence in Israel and believe the new representative office will be mutually beneficial to WuXi and the Israeli biotech industry,” said Tomer Kariv, chief executive officer of Pontifax.
 
“We are excited to establish a presence in Israel and to contribute to one of the most dynamic healthcare innovation ecosystems in the world,” said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. “We value the expertise that Pontifax has developed in Israel’s biotech industry and look forward to working closely with them to help many of their portfolio companies and other startup companies. This step advances WuXi’s mission of helping entrepreneurs in the global life sciences industry to realize their dreams of developing innovative products to benefit the world’s patients.”